A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

Satish Rao, Anthony J. Lembo, Steven J. Shiff, Bernard J. Lavins, Mark G. Currie, Xinwei D. Jia, Kelvin Shi, James E. MacDougall, James Z. Shao, Paul Eng, Susan M. Fox, Harvey A. Schneier, Caroline B. Kurtz, Jeffrey M. Johnston

Research output: Contribution to journalArticle

211 Citations (Scopus)

Abstract

Objectives: Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). Methods: This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μg oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points, the Food and Drug Administration's (FDA's) primary end point for IBS-C (responder: improvement of 30% in average daily worst abdominal pain score and increase by 1 complete spontaneous bowel movement (CSBM) from baseline (same week) for at least 50% of weeks assessed) and three other primary end points, based on improvements in abdominal pain and CSBMs for 9/12 weeks. Adverse events (AEs) were monitored. Results: The trial evaluated 800 patients (mean age43.5 years, female90.5%, white76.9%). The FDA end point was met by 136/405 linaclotide-treated patients (33.6%), compared with 83/395 placebo-treated patients (21.0%) (P0.0001) (number needed to treat: 8.0, 95% confidence interval: 5.4, 15.5). A greater percentage of linaclotide patients, compared with placebo patients, reported for at least 6/12 treatment period weeks, a reduction of 30% in abdominal pain (50.1 vs. 37.5%, P0.0003) and an increase of 1 CSBM from baseline (48.6 vs. 29.6%, P0.0001). A greater percentage of linaclotide patients vs. placebo patients were also responders for the other three primary end points (P0.05). Significantly greater improvements were seen in linaclotide vs. placebo patients for all secondary end points (P0.001). During the RW period, patients remaining on linaclotide showed sustained improvement; patients re-randomized from linaclotide to placebo showed return of symptoms, but without worsening of symptoms relative to baseline. Diarrhea, the most common AE, resulted in discontinuation of 5.7% of linaclotide and 0.3% of placebo patients. Conclusions: Linaclotide significantly improved abdominal pain and bowel symptoms associated with IBS-C for at least 12 weeks; there was no worsening of symptoms compared with baseline following cessation of linaclotide during the RW period.

Original languageEnglish (US)
Pages (from-to)1714-1724
Number of pages11
JournalAmerican Journal of Gastroenterology
Volume107
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Irritable Bowel Syndrome
Constipation
Randomized Controlled Trials
Safety
Placebos
Abdominal Pain
United States Food and Drug Administration
linaclotide
Numbers Needed To Treat
Guanylate Cyclase
Diarrhea

ASJC Scopus subject areas

  • Hepatology
  • Gastroenterology

Cite this

A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. / Rao, Satish; Lembo, Anthony J.; Shiff, Steven J.; Lavins, Bernard J.; Currie, Mark G.; Jia, Xinwei D.; Shi, Kelvin; MacDougall, James E.; Shao, James Z.; Eng, Paul; Fox, Susan M.; Schneier, Harvey A.; Kurtz, Caroline B.; Johnston, Jeffrey M.

In: American Journal of Gastroenterology, Vol. 107, No. 11, 01.11.2012, p. 1714-1724.

Research output: Contribution to journalArticle

Rao, S, Lembo, AJ, Shiff, SJ, Lavins, BJ, Currie, MG, Jia, XD, Shi, K, MacDougall, JE, Shao, JZ, Eng, P, Fox, SM, Schneier, HA, Kurtz, CB & Johnston, JM 2012, 'A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation', American Journal of Gastroenterology, vol. 107, no. 11, pp. 1714-1724. https://doi.org/10.1038/ajg.2012.255
Rao, Satish ; Lembo, Anthony J. ; Shiff, Steven J. ; Lavins, Bernard J. ; Currie, Mark G. ; Jia, Xinwei D. ; Shi, Kelvin ; MacDougall, James E. ; Shao, James Z. ; Eng, Paul ; Fox, Susan M. ; Schneier, Harvey A. ; Kurtz, Caroline B. ; Johnston, Jeffrey M. / A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation. In: American Journal of Gastroenterology. 2012 ; Vol. 107, No. 11. pp. 1714-1724.
@article{907d43158a4641f8a2fbc32e8d3b35fd,
title = "A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation",
abstract = "Objectives: Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). Methods: This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μg oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points, the Food and Drug Administration's (FDA's) primary end point for IBS-C (responder: improvement of 30{\%} in average daily worst abdominal pain score and increase by 1 complete spontaneous bowel movement (CSBM) from baseline (same week) for at least 50{\%} of weeks assessed) and three other primary end points, based on improvements in abdominal pain and CSBMs for 9/12 weeks. Adverse events (AEs) were monitored. Results: The trial evaluated 800 patients (mean age43.5 years, female90.5{\%}, white76.9{\%}). The FDA end point was met by 136/405 linaclotide-treated patients (33.6{\%}), compared with 83/395 placebo-treated patients (21.0{\%}) (P0.0001) (number needed to treat: 8.0, 95{\%} confidence interval: 5.4, 15.5). A greater percentage of linaclotide patients, compared with placebo patients, reported for at least 6/12 treatment period weeks, a reduction of 30{\%} in abdominal pain (50.1 vs. 37.5{\%}, P0.0003) and an increase of 1 CSBM from baseline (48.6 vs. 29.6{\%}, P0.0001). A greater percentage of linaclotide patients vs. placebo patients were also responders for the other three primary end points (P0.05). Significantly greater improvements were seen in linaclotide vs. placebo patients for all secondary end points (P0.001). During the RW period, patients remaining on linaclotide showed sustained improvement; patients re-randomized from linaclotide to placebo showed return of symptoms, but without worsening of symptoms relative to baseline. Diarrhea, the most common AE, resulted in discontinuation of 5.7{\%} of linaclotide and 0.3{\%} of placebo patients. Conclusions: Linaclotide significantly improved abdominal pain and bowel symptoms associated with IBS-C for at least 12 weeks; there was no worsening of symptoms compared with baseline following cessation of linaclotide during the RW period.",
author = "Satish Rao and Lembo, {Anthony J.} and Shiff, {Steven J.} and Lavins, {Bernard J.} and Currie, {Mark G.} and Jia, {Xinwei D.} and Kelvin Shi and MacDougall, {James E.} and Shao, {James Z.} and Paul Eng and Fox, {Susan M.} and Schneier, {Harvey A.} and Kurtz, {Caroline B.} and Johnston, {Jeffrey M.}",
year = "2012",
month = "11",
day = "1",
doi = "10.1038/ajg.2012.255",
language = "English (US)",
volume = "107",
pages = "1714--1724",
journal = "American Journal of Gastroenterology",
issn = "0002-9270",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - A 12-week, randomized, controlled trial with a 4-week randomized withdrawal period to evaluate the efficacy and safety of linaclotide in irritable bowel syndrome with constipation

AU - Rao, Satish

AU - Lembo, Anthony J.

AU - Shiff, Steven J.

AU - Lavins, Bernard J.

AU - Currie, Mark G.

AU - Jia, Xinwei D.

AU - Shi, Kelvin

AU - MacDougall, James E.

AU - Shao, James Z.

AU - Eng, Paul

AU - Fox, Susan M.

AU - Schneier, Harvey A.

AU - Kurtz, Caroline B.

AU - Johnston, Jeffrey M.

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Objectives: Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). Methods: This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μg oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points, the Food and Drug Administration's (FDA's) primary end point for IBS-C (responder: improvement of 30% in average daily worst abdominal pain score and increase by 1 complete spontaneous bowel movement (CSBM) from baseline (same week) for at least 50% of weeks assessed) and three other primary end points, based on improvements in abdominal pain and CSBMs for 9/12 weeks. Adverse events (AEs) were monitored. Results: The trial evaluated 800 patients (mean age43.5 years, female90.5%, white76.9%). The FDA end point was met by 136/405 linaclotide-treated patients (33.6%), compared with 83/395 placebo-treated patients (21.0%) (P0.0001) (number needed to treat: 8.0, 95% confidence interval: 5.4, 15.5). A greater percentage of linaclotide patients, compared with placebo patients, reported for at least 6/12 treatment period weeks, a reduction of 30% in abdominal pain (50.1 vs. 37.5%, P0.0003) and an increase of 1 CSBM from baseline (48.6 vs. 29.6%, P0.0001). A greater percentage of linaclotide patients vs. placebo patients were also responders for the other three primary end points (P0.05). Significantly greater improvements were seen in linaclotide vs. placebo patients for all secondary end points (P0.001). During the RW period, patients remaining on linaclotide showed sustained improvement; patients re-randomized from linaclotide to placebo showed return of symptoms, but without worsening of symptoms relative to baseline. Diarrhea, the most common AE, resulted in discontinuation of 5.7% of linaclotide and 0.3% of placebo patients. Conclusions: Linaclotide significantly improved abdominal pain and bowel symptoms associated with IBS-C for at least 12 weeks; there was no worsening of symptoms compared with baseline following cessation of linaclotide during the RW period.

AB - Objectives: Linaclotide is a minimally absorbed guanylate cyclase-C agonist. The objective of this trial was to determine the efficacy and safety of linaclotide in patients with irritable bowel syndrome with constipation (IBS-C). Methods: This phase 3, double-blind, parallel-group, placebo-controlled trial randomized IBS-C patients to placebo or 290 μg oral linaclotide once daily in a 12-week treatment period, followed by a 4-week randomized withdrawal (RW) period. There were four primary end points, the Food and Drug Administration's (FDA's) primary end point for IBS-C (responder: improvement of 30% in average daily worst abdominal pain score and increase by 1 complete spontaneous bowel movement (CSBM) from baseline (same week) for at least 50% of weeks assessed) and three other primary end points, based on improvements in abdominal pain and CSBMs for 9/12 weeks. Adverse events (AEs) were monitored. Results: The trial evaluated 800 patients (mean age43.5 years, female90.5%, white76.9%). The FDA end point was met by 136/405 linaclotide-treated patients (33.6%), compared with 83/395 placebo-treated patients (21.0%) (P0.0001) (number needed to treat: 8.0, 95% confidence interval: 5.4, 15.5). A greater percentage of linaclotide patients, compared with placebo patients, reported for at least 6/12 treatment period weeks, a reduction of 30% in abdominal pain (50.1 vs. 37.5%, P0.0003) and an increase of 1 CSBM from baseline (48.6 vs. 29.6%, P0.0001). A greater percentage of linaclotide patients vs. placebo patients were also responders for the other three primary end points (P0.05). Significantly greater improvements were seen in linaclotide vs. placebo patients for all secondary end points (P0.001). During the RW period, patients remaining on linaclotide showed sustained improvement; patients re-randomized from linaclotide to placebo showed return of symptoms, but without worsening of symptoms relative to baseline. Diarrhea, the most common AE, resulted in discontinuation of 5.7% of linaclotide and 0.3% of placebo patients. Conclusions: Linaclotide significantly improved abdominal pain and bowel symptoms associated with IBS-C for at least 12 weeks; there was no worsening of symptoms compared with baseline following cessation of linaclotide during the RW period.

UR - http://www.scopus.com/inward/record.url?scp=84869493876&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84869493876&partnerID=8YFLogxK

U2 - 10.1038/ajg.2012.255

DO - 10.1038/ajg.2012.255

M3 - Article

C2 - 22986440

AN - SCOPUS:84869493876

VL - 107

SP - 1714

EP - 1724

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

SN - 0002-9270

IS - 11

ER -